• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Anal Cancer - Pipeline Review, H2 2012 Product Image

Anal Cancer - Pipeline Review, H2 2012

  • Published: October 2012
  • 68 pages
  • Global Markets Direct

Anal Cancer – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Anal Cancer - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Anal Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Anal Cancer. Anal Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Anal Cancer.
- A review of the Anal Cancer products under development by companies and universities/research institutes based on information derived from READ MORE >

2
List of Tables 5
List of Figures 5
Introduction 6
REPORT COVERAGE 6
Anal Cancer Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Anal Cancer 8
Anal Cancer Therapeutics under Development by Companies 10
Anal Cancer Therapeutics under Investigation by Universities/Institutes 11
Late Stage Products 13
Comparative Analysis 13
Mid Clinical Stage Products 14
Comparative Analysis 14
Early Clinical Stage Products 15
Comparative Analysis 15
Pre-Clinical Stage Products 16
Comparative Analysis 16
Anal Cancer Therapeutics – Products under Development by Companies 17
Anal Cancer Therapeutics – Products under Investigation by Universities/Institutes 18
Companies Involved in Anal Cancer Therapeutics Development 19
PDS Biotechnology Corporation 19
ISA Pharmaceuticals B.V. 20
Anal Cancer – Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Combination Products 22
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
PDS-0101 - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Irinotecan + Oxaliplatin - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Radiation Therapy + Fluorouracil + Mitomycin C + Cisplatin - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Radiation Therapy + Fluorouracil + Cisplatin - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Cisplatin + Fluorouracil + Radiation Therapy - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Recombinant Human Interleukin-12 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Fluorouracil + Cetuximab + Cisplatin + Radiation therapy - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Cetuximab + Cisplatin + Fluorouracil - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 40
Fluorouracil + Mitomycin C + Radiation Therapy - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Cisplatin + Fluorouracil + Radiation Therapy - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Cetuximab + Fluoroucacil + Cisplatin + Radiation Therapy - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Xeloda + Eloxatin - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
5-Fluorouracil + Mitomycin C + Radiation Therapy - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
S-1 + Mitomycin C + Radiotherapy - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
5-Fluorouracil + Cisplatin - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Cisplatin + Fluorouracil + Mitomycin C + Radiation Therapy - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
sunitinib malate - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Vorinostat + Paclitaxel + Carboplatin - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 56
Vectibix + Mitomicin C + 5-Fluorouracil + Radiation Therapy - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
MTS-01 + 5-Fluorouracil + Mitomycin-C + Radiation Therapy - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
HPV-SLP Vaccine - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Anal Cancer Therapeutics – Drug Profile Updates 61
Anal Cancer Therapeutics – Discontinued Products 62
Anal Cancer Therapeutics - Dormant Products 63
Anal Cancer – Product Development Milestones 64
Featured News & Press Releases 64
Jan 19, 2012: National Advisory Committee On Immunization Recommends Merck's GARDASIL 64
Apr 06, 2011: U.S. Prescribing Information for GARDASIL Updated; Indication Not Granted for Use in Adult Women 64
Feb 02, 2011: Merck Announces New England Journal Of Medicine Publishes Efficacy And Safety Data For GARDASIL In Males 64
Dec 22, 2010: US FDA Approves New Indication for Merck's HPV Vaccine, GARDASIL 65
Nov 17, 2010: Merck Announces FDA Advisory Committee Supports Approval Of GARDASIL For Prevention Of Anal Cancer And AIN 66
Oct 16, 2009: FDA Approves GARDASIL for Use in Boys and Young Men 66
Appendix 67
Methodology 67
Coverage 67
Secondary Research 67
Primary Research 67
Expert Panel Validation 67
Contact Us 68
Disclaimer 68

List of Tables
Number of Products Under Development for Anal Cancer, H2 2012 8
Products under Development for Anal Cancer – Comparative Analysis, H2 2012 9
Number of Products under Development by Companies, H2 2012 10
Number of Products under Investigation by Universities/Institutes, H2 2012 12
Comparative Analysis by Late Stage Development, H2 2012 13
Comparative Analysis by Mid Clinical Stage Development, H2 2012 14
Comparative Analysis by Early Clinical Stage Development, H2 2012 15
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 16
Products under Development by Companies, H2 2012 17
Products under Investigation by Universities/Institutes, H2 2012 18
PDS Biotechnology Corporation, H2 2012 19
ISA Pharmaceuticals B.V., H2 2012 20
Assessment by Monotherapy Products, H2 2012 21
Assessment by Combination Products, H2 2012 22
Assessment by Stage and Route of Administration, H2 2012 24
Assessment by Stage and Molecule Type, H2 2012 26
Anal Cancer Therapeutics – Drug Profile Updates 61
Anal Cancer Therapeutics – Discontinued Products 62
Anal Cancer Therapeutics – Dormant Products 63

List of Figures
Number of Products under Development for Anal Cancer, H2 2012 8
Products under Development for Anal Cancer – Comparative Analysis, H2 2012 9
Products under Development by Companies, H2 2012 10
Products under Investigation by Universities/Institutes, H2 2012 11
Late Stage Products, H2 2012 13
Mid Clinical Stage Products, H2 2012 14
Early Clinical Stage Products, H2 2012 15
Pre-Clinical Stage Products, H2 2012 16
Assessment by Monotherapy Products, H2 2012 21
Assessment by Combination Products, H2 2012 22
Assessment by Route of Administration, H2 2012 23
Assessment by Stage and Route of Administration, H2 2012 24
Assessment by Molecule Type, H2 2012 25
Assessment by Stage and Molecule Type, H2 2012 26

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos